Torrent Pharmaceuticals Limited: Business Overview, Financials & Competitive Analysis
Torrent Pharmaceuticals Limited scores 7/10 on the AskCyborg Cyborg Score (Strong). Diversified Indian pharma leader with consistent revenue growth, expanding margins, and positive analyst sentiment offering long-term upside in emerging markets. Torrent demonstrated double-digit earnings growth in 2024 with 7.35% revenue growth and 15.39% earnings growth. Analyst consensus from Citi maintains a Buy rating with a 20.7% upside target. The.
What is Torrent Pharmaceuticals Limited's industry? Torrent Pharmaceuticals Limited (torrentpharma.com) operates in Pharmaceuticals - Branded and Generic. AskCyborg classifies Torrent Pharmaceuticals Limited under Pharmaceuticals - Branded and Generic in its company registry.
Torrent Pharmaceuticals is an India-based pharmaceutical company engaged in research, development, manufacturing, marketing, and distribution of branded and generic pharmaceutical formulations across India, the US, Br...
Cyborg Score thesis
Diversified Indian pharma leader with consistent revenue growth, expanding margins, and positive analyst sentiment offering...
Read the full analyst-debate transcript →Get the Latest Torrent Pharmaceuticals Limited Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeTorrent Pharmaceuticals Limited Overview
Pro stress-test →Torrent Pharmaceuticals is an India-based pharmaceutical company engaged in research, development, manufacturing, marketing, and distribution of branded and generic pharmaceutical formulations across India, the US, Brazil, Germany, and internationally. The company operates across multiple therapeutic areas including cardiovascular, anti-diabetic, anti-microbial, oncology, gastro-intestinal, pain management, and vitamins, minerals, and nutrients.
Strategic Profile
Pro stress-test →As one of India's leading pharmaceutical companies incorporated in 1959, Torrent is focused on producing high-quality, affordable medicines for a wide range of diseases. The company demonstrated strong financial momentum in 2024, with revenue reaching ₹115.16 billion (up 7.35% year-over-year) and earnings of ₹19.11 billion (up 15.39%).
Competitive Landscape
Pro stress-test →Torrent operates in India's highly fragmented pharmaceutical market competing against integrated players like Sun Pharma, Cipla, Lupin, and Dr. Reddy's Labs, as well as international companies. The company differentiates through therapeutic focus areas (cardiovascular, CNS, GI) and geographic reach across developed and emerging markets.
Industry Context
Torrent Pharmaceuticals Limited operates in Pharmaceuticals - Branded and Generic.
Key facts
Founded: 1959 · Headquarters: Ahmedabad, India · Revenue: ₹115.16B (2024) · Market cap: ₹154,000 Cr (~$18.5B)